Canaccord reiterates Hims & Hers stock rating on peptide launch
Canaccord Genuity reiterated a Buy rating and $40 price target for Hims & Hers Health (HIMS) after its launch of Peptides+ treatment line. The company reported Q3 revenue of $890M, up 49% YoY, but saw a subscriber decline. Analysts have mixed views on its outlook, with some lowering price targets due to subscriber losses and others optimistic about future growth.
How this was made
The 30-second read
Why it matters
Analyst upgrade with a $40 target may attract new buying, but subscriber churn and regulatory approvals for future peptides pose risks.
Market read
The combination of a product launch and an analyst rating upgrade creates a short‑term catalyst for HIMS, with potential upside if the peptide line gains traction.
What to watch
Potential supply‑chain constraints for BPC‑157 and TB‑500 and the sequential subscriber decline could temper growth.
Background
Hims & Hers Health (NYSE:HIMS) reported Q3 results and announced a new Peptides+ line, prompting analyst rating reaffirmation and a higher price target.
Ticker impact
Canaccord Genuity reiterated a Buy rating and raised the price target to $40 following Hims & Hers Health's launch of its new Peptides+ treatment line.
likely upward pressure as investors price in the higher target and growth potential of the peptide line
Analyst upgrade with a concrete $40 target and a novel product launch provide a clear catalyst for short‑term upside.
Market effects
The launch highlights growing interest in specialty injectable therapies, potentially benefiting other biotech firms in the peptide/anti‑aging space.
U.S. biotech sector may see modest uplift as investors reassess pipeline valuations.
Limited to U.S. listed biotech; no immediate global macro impact.
Counterpoint
The peptide market is still nascent and regulatory risk remains; the $40 target may be overly optimistic given uncertain reimbursement.
Key entities
- AnalystCanaccord Genuity
Equity research firm that reiterated a Buy rating and set a $40 price target.
- CompanyHims & Hers Health
Provider of telehealth and wellness products launching the Peptides+ line.




